A Phase 2 interventional study of M5717 60 mg and Pyronaridine in Malaria Infection, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 4 sites in 4 countries. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Malaria, Falciparum with a site in Burkina Faso — 6 open to participants now, 11 under way, none of them phase 3. Malaria, Falciparum · Burkina Faso.
Among the 52 studies in Malaria, Falciparum with a site in Burkina Faso, this one is the 29th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2023, is one of 15 in phase 2, and was the 37th registered.
456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.
Browse Malaria, Falciparum studies →6 of the 52 studies in Malaria, Falciparum with a site in Burkina Faso are open now. Recruiting first, the newest first:
Clinton Health Access Initiative Inc. · Sites in Burkina Faso, Uganda
Ages 5 mo–5 yrs
Sanaria Inc. · Sites in Burkina Faso
Ages 18–50 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Burkina Faso, Côte D'Ivoire, Gabon and 4 more countries
Ages 2–12
Serum Institute of India Pvt. Ltd. · Sites in Burkina Faso, Côte D'Ivoire, Nigeria and 1 more country
Ages 5 mo+ · Healthy volunteers
Novartis Pharmaceuticals · Sites in Burkina Faso, Côte D'Ivoire, Gabon and 3 more countries
Ages 2–100
A study can be open while its sites in Burkina Faso have not opened yet or have stopped. Only those recruiting at a site in Burkina Faso →
Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.
This study: 12 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 17 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2023.
This study's enrollment of 192 is above the median of 126 across 376 interventional studies indexed under Malaria, Falciparum.
Median enrollment 360 across the 46 interventional studies, 658 across the 6 observational. Of the 39 that completed or were terminated, 18 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Merck KGaA, Darmstadt, Germany has 4 studies filed under Malaria, Falciparum — fewer than ten, so there is no comparison to draw.
7 of the studies in Malaria, Falciparum with a site in Burkina Faso that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07385287Sanaria Inc.Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults | 2027-02 |
| NCT07811908Novartis PharmaceuticalsPlatform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) | 2027-02-04 |
| NCT06958198University of OxfordA Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) | 2027-03 |
| NCT07183371University of OxfordA Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M | 2027-03 |
| NCT07074665University of OxfordDose Finding Trial of R21/Matrix-M in School Children | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 52 studies in Malaria, Falciparum with a site in Burkina Faso, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants \>= 65 kilogram \[kg\]) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Drug: M5717 60 mg · Drug: Pyronaridine
Participants received single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Drug: Pyronaridine · Drug: M5717 200 mg
Participants received single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Drug: Pyronaridine · Drug: M5717 660mg
Participants received orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.
Drug: Atovaquone-Proguanil
Participants received single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
Participants received Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
Also known as: Pyronaridine tetraphosphate
Participants received Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
Participants received single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
Participants received single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
Time to Parasitemia Since Negative Blood Smear After Treatment
The time (in days) to first recorded parasitemia (parasite count \>0) since the first negative blood smear (parasite count of 0) after treatment (followed at least by 1 subsequent visit with a negative blood film), i.e. the time without a positive blood smear. Median time and 95% CI was estimated using the Kaplan Meier method for each cohort.
Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)
Percentage of Participants With Parasitemia (Positive Blood Smear)
Percentage of participants with a positive blood smear (parasitemia) was reported. Parasitemia is the presence of parasites in blood (parasite count \>0).
Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)
Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections)
Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to new Infections as determined by Genotyping using PCR Techniques) was reported.
Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)
Percentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence)
Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to Recrudescence as determined by Genotyping using PCR Techniques) was reported.
Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)
Parasite Clearance Time
Parasite clearance time defined as time from dosing to the first negative (no parasites) blood film (microscopy). Median parasite clearance time was estimated by Kaplan-Meier method
Time frame: Time from dosing to the first negative (no parasites) blood film (microscopy) , assessed up to 12 weeks
Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Treatment Related TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.
Time frame: Up to End of Study (approximately 12 Weeks)
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine
Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Apparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Maximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine
Cmax was obtained directly from the concentration versus time curve.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Apparent Terminal Half-life (t1/2) of M5717 and Pyronaridine
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Time to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine
The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
| Milestone | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Started | 49 | 47 | 48 | 48 |
| Completed | 29 | 27 | 32 | 32 |
| Not completed | 20 | 20 | 16 | 16 |
| Withdrew: Lack of efficacy | 19 | 19 | 15 | 15 |
| Withdrew: Other: the parent of the participant who is a minor, withdrew the participant from the trial | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
The time (in days) to first recorded parasitemia (parasite count \>0) since the first negative blood smear (parasite count of 0) after treatment (followed at least by 1 subsequent visit with a negative blood film), i.e. the time without a positive blood smear. Median time and 95% CI was estimated using the Kaplan Meier method for each cohort.
| days | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Time to Parasitemia Since Negative Blood Smear After Treatment | 62.0 (49.0 to 100.0) | 60.0 (47.0 to 100.0) | NA (61.0 to 100.0) | NA (59.0 to 100.0) |
Percentage of participants with a positive blood smear (parasitemia) was reported. Parasitemia is the presence of parasites in blood (parasite count \>0).
| percentage of participants | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Percentage of Participants With Parasitemia (Positive Blood Smear) | 53.1 | 51.1 | 35.4 | 37.5 |
Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to new Infections as determined by Genotyping using PCR Techniques) was reported.
| percentage of participants | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections) | 40.8 | 36.2 | 29.2 | 31.3 |
Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to Recrudescence as determined by Genotyping using PCR Techniques) was reported.
| percentage of participants | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Percentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence) | 4.1 | 12.8 | 4.2 | 4.2 |
Parasite clearance time defined as time from dosing to the first negative (no parasites) blood film (microscopy). Median parasite clearance time was estimated by Kaplan-Meier method
| hours | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Parasite Clearance Time | 24.1 (6.2 to 39.0) | 24.2 (12.2 to 39.8) | 24.0 (12.1 to 48.2) | 25.0 (24.1 to 48.0) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.
| Participants | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Participants with TEAEs | 31 | 27 | 31 | 28 |
| Participants with Serious TEAEs | 0 | 1 | 0 | 0 |
| Participants with Treatment-related TEAEs | 6 | 11 | 5 | 8 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.
| hour*nanogram per milliliter(hour*ng/mL) | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine | 613.64 ± 1.1 | 2292.02 ± 0.5 | 9988.92 ± 0.4 | 5985.14 ± 0.5 | 6418.17 ± 0.3 |
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
| h*ng/mL | M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine | 205.87 ± 0.4 | 743.74 ± 0.5 | 3303.65 ± 0.4 | 1594.05 ± 0.6 | 1742.89 ± 0.4 |
Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| h*ng/mL | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 (660 mg) | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine | 455.40 ± 0.5 | 2040.41 ± 0.5 | 9635.73 ± 0.4 | 5393.62 ± 0.6 | 5793.71 ± 0.4 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf.
| Liter per Hours (L/h) | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Apparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine | 97.77 ± 1.1 | 87.25 ± 0.5 | 66.07 ± 0.4 | 90.22 ± 0.5 | 112.18 ± 0.3 |
Cmax was obtained directly from the concentration versus time curve.
| nanogram per milliliter (ng/mL) | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Maximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine | 15.19 ± 0.6 | 59.69 ± 0.6 | 254.50 ± 0.5 | 157.81 ± 0.6 | 166.46 ± 0.4 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
| hour | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of M5717 and Pyronaridine | 46.013 ± 1.3 | 64.663 ± 0.4 | 90.234 ± 0.5 | 264.15 ± 0.4 | 246.94 ± 0.6 |
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
| hour | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Time to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine | 4.067 (1.05 to 141.07) | 4.00 (1.00 to 12.10) | 4.00 (1.08 to 175.57) | 2.10 (1.00 to 7.42) | 2.08 (1.00 to 12.08) |
The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).
| liter | Cohort 1: M5717 60 mg | Cohort 2: M5717 200 mg | Cohort 3: M5717 660 mg | Cohort 1, 2 and 3: Pyronaridine 540 mg | Cohort 1, 2 and 3: Pyronaridine 720 mg |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine | 6490.76 ± 0.5 | 8140.36 ± 0.4 | 8601.43 ± 0.5 | 34383.091 ± 0.5 | 39966.70 ± 0.7 |
Collected over End of Study (approximately 12 Weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: M5717 (60 mg) + Pyronaridine | 0/49 (0%) | 0/49 (0%) | 31/49 (63.3%) |
| Cohort 2: M5717 (200 mg) + Pyronaridine | 0/47 (0%) | 1/47 (2.1%) | 27/47 (57.4%) |
| Cohort 3: M5717 (660 mg)+ Pyronaridine | 0/48 (0%) | 0/48 (0%) | 31/48 (64.6%) |
| Cohort 4: Atovaquone-proguanil | 0/48 (0%) | 0/48 (0%) | 28/48 (58.3%) |
| Event | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 0/49 | 1/47 | 0/48 | 0/48 |
| Event | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil |
|---|---|---|---|---|
| MalariaInfections and infestations | 14/49 | 12/47 | 10/48 | 7/48 |
| HeadacheNervous system disorders | 7/49 | 3/47 | 6/48 | 9/48 |
| Blood alkaline phosphatase increasedInvestigations | 5/49 | 6/47 | 3/48 | 7/48 |
| Blood bilirubin increasedInvestigations | 7/49 | 4/47 | 4/48 | 4/48 |
| Aspartate aminotransferase increasedInvestigations | 3/49 | 3/47 | 2/48 | 5/48 |
| DizzinessNervous system disorders | 1/49 | 2/47 | 5/48 | 1/48 |
| Upper respiratory tract infectionInfections and infestations | 3/49 | 4/47 | 4/48 | 2/48 |
| NasopharyngitisInfections and infestations | 4/49 | 2/47 | 2/48 | 1/48 |
| Urinary tract infectionInfections and infestations | 2/49 | 0/47 | 3/48 | 3/48 |
| HypercreatininaemiaMetabolism and nutrition disorders | 3/49 | 0/47 | 2/48 | 3/48 |
| Age, Continuous(Years) | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil | Total |
|---|---|---|---|---|---|
| Mean | 23 ± 8.6 | 24 ± 8.9 | 25 ± 9.2 | 25 ± 11.2 | 25 ± 9.5 |
| Sex: Female, Male(Participants) | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil | Total |
|---|---|---|---|---|---|
| Female | 20 | 16 | 20 | 19 | 75 |
| Male | 29 | 31 | 28 | 29 | 117 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: M5717 (60 mg) + Pyronaridine | Cohort 2: M5717 (200 mg) + Pyronaridine | Cohort 3: M5717 (660 mg)+ Pyronaridine | Cohort 4: Atovaquone-proguanil | Total |
|---|---|---|---|---|---|
| Ethnicity-Hispanic or Latino | 1 | 2 | 3 | 0 | 6 |
| Ethnicity-Not Hispanic or Latino | 48 | 45 | 44 | 48 | 185 |
| Ethnicity-Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race-Black or African American | 49 | 47 | 48 | 48 | 192 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
Data sharing details ↗ · bit.ly
Ran from Nov 2023 to primary completion in Dec 2024, 13 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabamiquine · Pyronaridine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →